{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:30:13Z","timestamp":1784763013060,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.atherosclerosis.2006.11.028","type":"journal-article","created":{"date-parts":[[2007,1,17]],"date-time":"2007-01-17T12:19:43Z","timestamp":1169036383000},"page":"505-511","source":"Crossref","is-referenced-by-count":25,"title":["Effect of rosuvastatin 5\u201320mg on triglycerides and other lipid parameters in Japanese patients with hypertriglyceridemia"],"prefix":"10.1016","volume":"194","author":[{"given":"Yasushi","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ebihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Yanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib1","first-page":"111","article-title":"A risk factor for atherosclerosis: triglyceride-rich lipoproteins","volume":"47","author":"Malloy","year":"2001","journal-title":"Adv Intern Med"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2006.11.028_bib2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0002-9149(00)01127-9","article-title":"Evidence that triglycerides are an independent coronary heart disease risk factor","volume":"86","author":"Cullen","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib3","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III Final Report). JAMA 2001; 285 (19): 2486\u201397.","DOI":"10.1001\/jama.285.19.2486"},{"issue":"Suppl. 4A","key":"10.1016\/j.atherosclerosis.2006.11.028_bib4","doi-asserted-by":"crossref","first-page":"66B","DOI":"10.1016\/S0002-9149(98)00041-1","article-title":"Comparison of statins in hypertriglyceridemia","volume":"81","author":"Stein","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00019501-200403000-00008","article-title":"Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia","volume":"15","author":"Hunninghake","year":"2004","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1253\/circj.68.107","article-title":"More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy","volume":"68","author":"Strutt","year":"2004","journal-title":"Circ J"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5551\/jat.10.329","article-title":"Randomized dose\u2013response study of rosuvastatin in Japanese patients with hypercholesterolemia","volume":"10","author":"Saito","year":"2003","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5551\/jat.11.152","article-title":"Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia","volume":"11","author":"Mabuchi","year":"2004","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.curtheres.2005.04.004","article-title":"Status of lipid-lowering therapy prescribed based on recommendations in the 2002 Report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: a study of the Japan Lipid Assessment Program (J-LAP)","volume":"66","author":"The J-LAP Investigators","year":"2005","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib10","doi-asserted-by":"crossref","unstructured":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21\u20137.","DOI":"10.1161\/01.CIR.102.1.21"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib11","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib12","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0021-9150(94)90124-4","article-title":"Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia","volume":"106","author":"Homma","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib14","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0735-1097(98)00442-2","volume":"32","author":"Ruotolo","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib15","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.105.565135","article-title":"Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial","volume":"113","author":"Otvos","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib16","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.161.11.1413","article-title":"Non-high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality","volume":"161","author":"Cui","year":"2001","journal-title":"Arch Intern Med"},{"issue":"Suppl. 4A","key":"10.1016\/j.atherosclerosis.2006.11.028_bib17","doi-asserted-by":"crossref","first-page":"26B","DOI":"10.1016\/S0002-9149(98)00034-4","article-title":"Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy","volume":"81","author":"Frost","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib18","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.105.583336","article-title":"Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is \u2026","volume":"112","author":"Sniderman","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/eurheartj\/ehi003","article-title":"Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA\/KORA Augsburg cohort study","volume":"26","author":"Meisinger","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2006.11.028_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment","volume":"78","author":"Lee","year":"2005","journal-title":"Clin Pharmacol Ther"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915006007040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915006007040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T20:28:05Z","timestamp":1556051285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915006007040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0021915006007040"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2006.11.028","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}